Ultragenyx Pharmaceutical Inc. (RARE) AI Stock Analysis

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on identifying, acquiring, developing, and commercializing therapies for rare and ultra-rare genetic diseases across North America, Europe, and other regions. Its commercialized biologic portfolio includes Crysvita for X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii for Mucopolysaccharidosis VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia. The company is also advancing clinical pipeline candidates including gene therapies DTX401 and DTX301, monoclonal antibody UX143, antisense oligonucleotide GTX-102, as well as UX701 and UX053.

Ultragenyx grew annual revenue from $351.4M in FY2021 to $673.0M in FY2025, reflecting a 5-year revenue CAGR of 19.9%. Over that timeframe, gross margin compressed from 95.4% in FY2021 to 83.8% in FY2025. Operating margins improved from -108.6% in FY2021 to -79.5% in FY2025 as research and development expenses reached $750.0M. For FY2025, net income was -$575.0M, or -$5.84 per share. Trailing twelve month revenue reached $717.0M through June 30, 2026, with quarterly revenue growing 28.1% year-over-year. TTM operating margin stood at -35.0% and profit margin was -81.7%, resulting in a TTM diluted EPS of -$5.82.

As of June 30, 2026, Ultragenyx held $292.0M in cash and short-term investments against $1.20B in total debt, leaving net debt at $910.0M. The company operates with negative shareholders' equity of -$291.0M, though its current ratio was 1.73 on total assets of $1.26B. Cash flow from operations was -$466.0M in FY2025, and free cash flow was -$472.0M after $6.0M of capital expenditures. Over the past five years, the company's share count increased 48.6%.

Ultragenyx trades at a price-to-sales ratio of 2.0x and an enterprise-value-to-revenue ratio of 1.1x, below the median of its US-listed Healthcare peers at 4.1x price-to-sales. Its price-to-book ratio is 19.7x. The company's market capitalization is $1.43B, while enterprise value stands at $824.0M. Over the past year, RARE shares fell 57.2%, compared to a 16.8% gain for the S&P 500 (SPY). Over five years, the stock dropped 81.8% while the S&P 500 advanced 83.0%.

Wall Street analysts maintain 8 Strong Buy, 2 Buy, and 11 Hold ratings on RARE, with no Sell or Strong Sell ratings. The mean price target is $26.25, representing an 80.5% upside from the last close of $14.54. For FY2026, consensus estimates project an EPS of -$4.08 on revenue of $759.6M. For the next fiscal year, six analysts project positive EPS of $0.23 on $989.3M in revenue. Ultragenyx beat EPS estimates in 1 of the last 4 quarters, with its next earnings report scheduled for November 3, 2026.

This page is an AI-written research summary of Ultragenyx Pharmaceutical Inc. (RARE). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RARE income statement, RARE balance sheet, RARE key metrics, RARE analyst forecast, RARE chart. See the RARE stock overview for the latest quote and news.